New York, NY – In a landmark discovery poised to redefine cancer immunotherapy, researchers at the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) have unraveled a long-standing paradox surrounding regulatory T (Treg) cells in colorectal cancer. Published in the prestigious scientific journal Immunity, their findings reveal that Treg cells, traditionally viewed as immune suppressors that hinder the body’s fight against cancer, exhibit a dual nature in colorectal tumors. This groundbreaking study identifies two distinct subtypes of Treg cells playing opposing roles: one surprisingly restrains tumor growth, while the other fuels it. This nuanced understanding not only offers a clear explanation for colorectal cancer’s unique immune profile but also opens promising new avenues for targeted treatments, particularly for the most common forms of the disease that currently resist standard immunotherapies.
The core revelation is that the sheer number of Treg cells in a tumor is less critical than their specific identity. For decades, the presence of numerous Treg cells in most solid tumors has been associated with worse patient outcomes, as these immune "brakes" dampen the body’s ability to mount an effective anti-cancer attack. Colorectal cancer, however, stood as a perplexing exception, where higher Treg cell counts often correlated with improved survival. This new research resolves that enigma, demonstrating that the beneficial subtype of Treg cells is responsible for this counterintuitive positive association. This paradigm shift underscores the urgent need for selective therapeutic approaches that can differentiate between these cellular allies and adversaries within the tumor microenvironment.
The Enigma of Colorectal Cancer’s Immune Landscape
For years, the scientific community grappled with the puzzling behavior of regulatory T cells in colorectal cancer (CRC). In the vast majority of solid tumors, these specialized immune cells are notorious for their immunosuppressive functions. Their primary role is to maintain "immune tolerance," preventing the immune system from attacking the body’s own healthy tissues, beneficial microbes, and innocuous environmental elements. While crucial for preventing autoimmune diseases, this suppressive capability becomes a significant liability in the context of cancer, where Treg cells can shield malignant cells from immune surveillance and attack, thereby promoting tumor progression and leading to poorer patient prognoses.
Yet, colorectal cancer consistently defied this established pattern. Clinical observations repeatedly showed that CRC tumors infiltrated with a higher density of Treg cells were often linked to longer survival times for patients. This stark contradiction posed a major hurdle for understanding CRC immunology and developing effective immunotherapies. Researchers were left with an unanswered question: why did colorectal cancer seemingly break the rules of tumor immunology? The lack of a clear explanation meant that treatment strategies remained broad, often failing to harness the full potential of the immune system in this prevalent and deadly disease.
Decades of Groundbreaking Research Pave the Way
The latest breakthrough from MSK is not an isolated discovery but the culmination of more than two decades of foundational research led by Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. Dr. Rudensky is widely recognized as one of the world’s foremost experts on regulatory T cells, having dedicated his career to unraveling their intricate biology. His pioneering work was instrumental in establishing the very concept of Treg cells and their critical role in maintaining immune tolerance.
Over the years, Dr. Rudensky’s lab has systematically mapped out the complex mechanisms governing Treg cell development, their diverse functions, and their profound influence on various physiological processes, including infection, autoimmunity, and, crucially, cancer development. This deep understanding of Treg cell biology provided the essential framework for the current investigation, enabling the MSK team to ask more precise questions about their specific roles within the heterogeneous environment of colorectal tumors. This rich historical context underscores the significance of the current findings, which build upon a robust scientific foundation to resolve a long-standing immunological mystery.
Unveiling the Dual Nature of Treg Cells: A Critical Distinction
The new study, spearheaded by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author, definitively demonstrates that "Treg cells are not all the same." This pivotal insight, published in Immunity, fundamentally reconfigures our understanding of these immune regulators in CRC.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Dr. Rudensky. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." This statement encapsulates the study’s core finding: the immune landscape of colorectal cancer is far more nuanced than previously imagined, demanding a precision-guided approach to immunotherapy.
Focusing on the Predominant Form: MSS-MMRp Colorectal Cancer
Colorectal cancer remains a formidable health challenge, ranking as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. The MSK study strategically focused on the most common form of the disease, which accounts for a staggering 80% to 85% of all colorectal cancers. These tumors are characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), indicating their DNA remains relatively stable.
Unfortunately, this prevalent subgroup of colorectal cancers has historically shown poor responsiveness to a class of immunotherapies known as checkpoint inhibitors. This stands in stark contrast to the less common, but often highly treatable, cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR), which frequently respond dramatically to immunotherapy alone, allowing many patients to avoid the arduous regimens of surgery, chemotherapy, and radiation. The lack of effective immunotherapy options for the vast majority of CRC patients—those with MSS-MMRp tumors—highlights the critical need for novel treatment strategies, making the MSK team’s findings particularly impactful for this underserved patient population.
Methodology: Peering into the Tumor Microenvironment
To dissect the unique immune dynamics within common colorectal cancers, the research team employed a sophisticated mouse model meticulously developed at MSK. This model was specifically engineered to closely mimic the genetic alterations, behavioral characteristics, and intricate immune environment observed in human colorectal tumors, providing a highly relevant platform for their investigations.
Through painstaking analysis of tumor-associated Treg cells within this model, the researchers made a crucial distinction: these cells naturally segregate into two primary groups. One group was found to produce a specific signaling molecule, or cytokine, known as interleukin-10 (IL-10). The other group, notably, did not produce IL-10. This phenotypic difference proved to be the key to unlocking their divergent functions.
The team then embarked on a series of detailed experiments involving the selective removal of each of these Treg groups. By precisely eliminating one subtype while preserving the other, they were able to isolate and observe the specific impact of each Treg population on tumor growth and progression. This rigorous experimental design allowed for an unambiguous identification of the opposing roles played by these seemingly similar immune cells.
The Dichotomy Revealed: IL-10 Positive vs. IL-10 Negative Tregs
The selective removal experiments yielded unequivocal results, clearly demonstrating the contrasting effects of the two Treg subtypes on tumor growth.
IL-10 Positive Tregs: The Unexpected Protectors
The research revealed that the Treg cells producing interleukin-10 (IL-10) played a surprisingly protective role in colorectal cancer. These IL-10-positive Treg cells actively helped to slow tumor growth. Their mechanism of action involved reducing the activity of another type of immune cell called Th17 cells. Th17 cells are known to produce interleukin 17 (IL-17), a cytokine that acts as a potent growth signal for tumors, promoting their proliferation and survival. By dampening the Th17-IL-17 axis, IL-10-positive Treg cells effectively curtailed this pro-tumorigenic pathway. Interestingly, these beneficial Treg cells were more frequently observed in the healthy tissue immediately surrounding the tumor rather than deep within the malignant mass itself. The experimental evidence was compelling: when IL-10-positive Treg cells were selectively removed from the mouse models, tumors grew significantly more quickly, underscoring their critical role in restraining disease progression.
IL-10 Negative Tregs: The Immunosuppressive Adversaries
In stark contrast, the Treg cells that did not produce IL-10 exhibited the classic immunosuppressive effects typically associated with regulatory T cells in other cancers. These IL-10-negative Treg cells were found to actively suppress the body’s most powerful immune defenders, particularly CD8+ T cells, which are renowned for their direct cancer-killing abilities. By inhibiting these cytotoxic T lymphocytes, the IL-10-negative Treg cells created an immune-privileged environment that allowed tumors to thrive. This harmful subtype was predominantly located within the tumor itself, suggesting a direct and potent influence on the immediate tumor microenvironment. Consistent with their detrimental role, when IL-10-negative Treg cells were eliminated from the mouse models, tumors became markedly smaller, demonstrating their role in fueling tumor growth.
Human Validation: Bridging Mouse Models to Patient Outcomes
To ensure the relevance of their findings to human disease, the MSK team meticulously validated their results using actual tumor samples obtained from people with colorectal cancer. In these patient samples, the researchers successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells, confirming that the cellular dichotomy observed in the mouse models accurately reflects the human condition.
Furthermore, the team undertook a comprehensive analysis of clinical outcomes for more than 100 colorectal cancer patients. This retrospective analysis provided crucial real-world evidence. Patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells demonstrated significantly longer survival rates. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer outcomes. This direct correlation between Treg subtype presence and patient survival unequivocally reinforced the functional distinction observed in the laboratory experiments.
"This research shows how important these positive cells are," affirms Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment underscores the transformative potential of these findings for guiding the development of more precise and effective cancer immunotherapies.
A New Therapeutic Frontier: Targeting CCR8
The identification of these two functionally distinct Treg subtypes offers a clear and promising path forward for improving treatment strategies, particularly for the vast majority of colorectal cancer patients who currently lack effective immunotherapy options. A key insight from the study is the discovery of a specific protein marker: the IL-10-negative Treg cells, which are the immune-suppressing and tumor-promoting subtype, were found to express high levels of a protein called CCR8. Importantly, these CCR8-high, harmful cells are primarily localized within the tumors themselves, making them an ideal target for selective intervention.
This finding gains even greater significance when viewed in the context of earlier work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. That research previously demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. This prior work laid the groundwork for the idea that antibodies could be engineered to specifically target and selectively remove these harmful CCR8-expressing Treg cells. The therapeutic promise lies in the ability to deplete the detrimental Tregs, thereby "releasing the brakes" on the immune system and allowing it to mount a more robust attack against the tumor, all while leaving the beneficial Treg cells intact to maintain essential immune tolerance in healthy tissues.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," states Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator. Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, investigating this innovative approach both as a standalone therapy and in combination with existing immunotherapies. The new MSK study provides compelling preclinical and clinical validation, strengthening the rationale for deploying this CCR8-targeting strategy in colorectal cancer and potentially extending its application to a broader spectrum of malignancies.
Beyond Colorectal Cancer: Broader Immunotherapeutic Implications
The implications of this research extend far beyond colorectal cancer. The MSK team embarked on a comprehensive analysis of a large dataset of T cells derived from 16 different cancer types. Their goal was to ascertain whether the same immune patterns – specifically, the division between IL-10-positive and IL-10-negative Treg cells – were discernible in other forms of cancer.
Remarkably, they found similar distinctions in several cancers affecting what are known as "barrier tissues," including the skin and the delicate linings of the mouth, throat, and stomach. These tissues share a common characteristic: they are constantly exposed to external microbes and environmental stresses, necessitating a robust and dynamic immune response for continuous defense and repair.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who spearheaded the intricate data analysis for the study, co-mentored by Dr. Leslie and Dr. Rudensky. This shared immunological environment suggests that the mechanisms governing Treg cell function in these barrier tissues might be fundamentally similar to those in the gut. Consequently, the researchers propose that therapeutic strategies designed to selectively remove IL-10-negative Treg cells in colorectal cancer could very well prove effective against these other cancers arising in analogous barrier tissues, opening up a much wider scope for this novel immunotherapeutic approach.
The Complexity of Metastatic Disease: A Different Immune Balance
While the findings offer profound insights into primary colorectal tumors, the researchers also explored the immune landscape of metastatic colorectal cancer, specifically focusing on disease that had spread to the liver. Here, they observed a notably different immune pattern.
In these advanced, metastatic tumors, the balance was heavily skewed: IL-10-negative Treg cells, the harmful subtype, greatly outnumbered the beneficial IL-10-positive cells. This altered proportion fundamentally shifted the therapeutic calculus. Unlike in primary tumors, where selective targeting of IL-10-negative Tregs is paramount, the removal of all Treg cells in the context of liver metastases actually caused the metastatic tumors to shrink. This suggests that in advanced disease, where the harmful Tregs are overwhelmingly dominant, a more aggressive, pan-Treg depletion strategy might be beneficial.
This crucial distinction highlights the imperative for treatment strategies that are not only tailored to the specific tissue involved but also finely tuned to the stage of the disease. The immune microenvironment of a primary tumor can differ significantly from its metastatic counterparts, demanding a flexible and adaptive approach to immunotherapy.
Conclusion: A Paradigm Shift in Cancer Immunotherapy
The groundbreaking research from Memorial Sloan Kettering Cancer Center represents a significant leap forward in our understanding of cancer immunology and a pivotal moment for colorectal cancer treatment. By resolving the long-standing paradox of Treg cells in CRC, the study has moved beyond a simplistic view of immune suppression to reveal a complex, dual-faceted role for these cells. The identification of beneficial IL-10-positive Tregs and detrimental IL-10-negative Tregs, along with the specific marker CCR8 for the latter, provides actionable targets for precision immunotherapy.
This work not only offers hope for the vast majority of colorectal cancer patients who currently lack effective immunotherapeutic options but also paves the way for broader applications in other common barrier tissue cancers. As CCR8-targeting antibodies advance through clinical trials, the promise of selectively disarming cancer’s immune shields while preserving essential immune tolerance inches closer to reality. The findings underscore a fundamental principle in modern oncology: moving beyond "one-size-fits-all" treatments towards highly personalized strategies that account for the intricate cellular dynamics within each patient’s unique tumor microenvironment and disease stage. This paradigm shift holds the potential to unlock more effective, less toxic, and ultimately life-saving therapies for millions worldwide.
Research Team, Funding, and Disclosures
Additional authors include: Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key contributors to the research: The Integrated Genomics Operation and the Single Cell Research Initiative at MSK played key roles in the research.
Funding was generously provided by: The National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Disclosures:
Dr. Rudensky serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
